Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Case Discussion on Stage IIIA N2 NSCLC, with Drs. Blumenschein & Curran
Dr West
Author
Howard (Jack) West, MD

Several weeks ago I had the opportunity to discuss a series of cases of locally advanced NSCLC with a couple of expert colleagues: Dr. George Blumenschein, medical oncologist in the Division of Thoracic & Head/Neck Oncology at MD Anderson Cancer Center in Houston, TX; and Dr. Walter Curran, radiation oncologist who heads the Division of Radiation Oncology at the Winship Cancer Center at Emory University in Atlanta, GA. Dr. Curran is also the head of the Radiation Therapy Oncology Group, the US-based cooperative oncology group leading important questions about radiation oncology in various cancer types.

The first of the cases we covered is a patient of mine with stage IIIA N2 NSCLC, the most controversial setting in lung cancer management, where many options are all considered as reasonable alternatives throughout the oncology field.

Here's the audio and video versions of the podcast, along with the transcript and figures.

stage-iiia-n2-nsclc-case-drs-blumenschein-and-curran-audio-podcast

stage-iiia-n2-nsclc-case-drs-blumenschein-and-curran-transcript

stage-iiia-n2-nsclc-case-drs-blumenschein-and-curran-figs

This will be followed by a discussion of a Pancoast tumor and then one of someone with an unresectable locally advanced NSCLC.

This program is supported by an educational grant from OSI Pharmaceuticals. We thank them for their support.

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on